System and method for monitoring thoracic fluid levels based on impedance using an implantable medical device
Techniques are provided for monitoring thoracic fluid levels based on thoracic impedance (Z T ) and cardiogenic impedance (Z C ). In one example, the implantable device tracks the maximum time rate of change in cardiogenic impedance (i.e. max(dZ C /dt)) to detect trends toward hypervolemic or hypovolemic states within the patient based on changes in heart contractility. The detection of these trends in combination with trends in thoracic impedance allows for a determination of whether the thoracic cavity of the patient is generally “too wet” or “too dry,” and thus allows for the titration of diuretics to avoid such extremes. In particular, a decrease in thoracic impedance (Z T ) in combination with a decrease in max (dZ C /dt) is indicative of the thorax being “too wet” (i.e. a fluid overload). Conversely, an increase in thoracic impedance (Z T ) in combination with a decrease in max (dZ C /dt) is indicative of the thorax being “too dry” (i.e. a fluid underload).
1. A method for monitoring thoracic fluids within a patient having an implantable medical device, the method comprising:
detecting thoracic impedance;
detecting cardiogenic impedance;
monitoring thoracic fluids based on a combination of thoracic impedance and cardiogenic impedance;
wherein monitoring thoracic fluids based on a combination of thoracic impedance and cardiogenic impedance includes detecting trends within thoracic impedance and detecting trends within time rate of change values derived from cardiogenic impedance;
wherein a decrease in thoracic impedance combined with a decrease in the time rate of change of cardiogenic impedance is deemed to be indicative of excess fluids within the thorax.
2. The method of claim 1 further including controlling therapy in response to changes in thoracic fluid levels.
3. The method of claim 2 wherein controlling therapy in response to changes in thoracic fluid levels includes one or more of initiating or increasing a dosage of diuretics in response to an excess of thoracic fluids.
4. The method of claim 2 wherein controlling therapy in response to changes in thoracic fluid levels includes one or more of suspending or decreasing a dosage of diuretics in response to a deficit of thoracic fluids.
5. The method of claim 2 wherein controlling therapy in response to changes in thoracic fluids includes controlling dosages of diuretics to maintain a thoracic fluid levels within a predetermined range.
6. The method of claim 2 wherein controlling therapy in response to changes in thoracic fluids is controlled by an expert system.
7. The method of claim 1 further including generating diagnostic information representative of changes in thoracic fluid levels.
8. The method of claim 1 further including generating warning signals indicative of thoracic fluid levels deviating from a predetermined range.
9. The method of claim 1 further including generating warning signals indicative of failure of prior therapy to maintain thoracic fluid levels within a predetermined range.
10. The method of claim 1 further including identify long-term trends within thoracic impedance and within cardiogenic impedance indicative of progression of heart failure.
11. The method of claim 1 wherein monitoring thoracic fluids based on a combination of thoracic impedance and cardiogenic impedance is performed by the implantable device.
12. The method of claim 1 wherein monitoring thoracic fluids based on a combination of thoracic impedance and cardiogenic impedance is performed by an external system based information transmitted from the implantable medical device.
13. The method of claim 1 wherein detecting thoracic impedance includes applying impedance detection pulses between one or more of a left ventricular (LV) coil shocking electrode or a LV pacing electrode and an electrode mounted to a housing of the implantable medical device.
14. The method of claim 1 wherein detecting cardiogenic impedance includes applying impedance detection pulses between at least two electrodes to obtain an impedance signal.
15. The method of claim 1 wherein detecting cardiogenic impedance includes applying impedance detection pulses between a right atrial (RA) electrode and an electrode mounted to a housing of the implantable medical device to obtain an RA-housing impedance signal.
16. A method for monitoring thoracic fluids within a patient having an implantable medical device, the method comprising:
detecting thoracic impedance;
detecting cardiogenic impedance;
monitoring thoracic fluids based on a combination of thoracic impedance and cardiogenic impedance;
wherein monitoring thoracic fluids based on a combination of thoracic impedance and cardiogenic impedance includes detecting trends within thoracic impedance and detecting trends within time rate of change values derived from cardiogenic impedance;
wherein an increase in thoracic impedance combined with a decrease in the time rate of change of cardiogenic impedance is deemed to be indicative of a deficit of fluids within the thorax.
17. A system for monitoring thoracic fluids within a patient having an implantable medical device implanted therein, the system comprising:
a thoracic impedance detector;
a cardiogenic impedance detector;
a thoracic fluid monitor that monitors thoracic fluids based on a combination of thoracic impedance and cardiogenic impedance;
wherein the thoracic fluid monitor monitors thoracic fluids based on a combination of thoracic impedance and cardiogenic impedance including detecting trends within thoracic impedance and detecting trends within time rate of change values derived from cardiogenic impedance;
wherein a decrease in thoracic impedance combined with a decrease in the time rate of change of cardiogenic impedance is deemed to be indicative of excess fluids within the thorax.
18. A system for monitoring thoracic fluids within a patient having an implantable medical device implanted therein, the system comprising:
a thoracic impedance detector;
a cardiogenic impedance detector;
a thoracic fluid monitor that monitors thoracic fluids based on a combination of thoracic impedance and cardiogenic impedance;
wherein the thoracic fluid monitor monitors thoracic fluids based on a combination of thoracic impedance and cardiogenic impedance including detecting trends within thoracic impedance and detecting trends within time rate of change values derived from cardiogenic impedance;
wherein an increase in thoracic impedance combined with a decrease in the time rate of change of cardiogenic impedance is deemed to be indicative of a deficit of fluids within the thorax.